Details of the Drug

General Information of Drug (ID: DMKOHC5)

Drug Name
Astegolimab
Synonyms RG6149; MSTT1041A
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 3 [1]
Asthma CA23 Phase 2 [2]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
DBAL18
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-1 receptor-like 1 (IL1RL1) TT4GZA4 ILRL1_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05878769) A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT02918019) A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma. U.S.National Institutes of Health.
3 Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022 May;10(5):469-477.